Efficacy of different regimens of intraperitoneal chemoperfusions with cisplatin in a rat model of ovarian cancer peritoneal carcinomatosis

3^rd World Congress on Cancer Science & Therapy

October 21-23, 2013 DoubleTree by Hilton Hotel San Francisco Airport, CA, USA

V. G. Bespalov, O. A. Belyaeva, A. N. Stukov, K. Yu. Senchik, G. S. Kireeva and V. A. Aristova

Accepted Abstracts: J Cancer Sci Ther

Abstract :

Currently hyperthermic intraperitoneal chemoperfusion (HIPEC) becomes an important part of peritoneal carcinomatosis treatment in patients with ovarian cancer. Cisplatin is commonly used at this treatment; however doses of the drug and chemoperfusion regimens are discussed. Comparative study of HIPEC and normothermal intraperitoneal chemotherapy (IPEC) with high-doses of cisplatin in a rat model of ovarian cancer peritoneal carcinomatosis was our purpose. Ovarian cancer cells were inoculated intraperitoneally (i.p.) in 99 Wistar female rats. We used cisplatin 48 hours after the i.p. tumor inoculation in maximal tolerable doses of 4 mg/kg for i.p. injection, 40 mg/kg for IPEC, and 20 mg/kg for HIPEC. In the rats of control group saline solution was administered i.p. at a volume of 0.5 ml. The antitumor effect of cisplatin was estimated by increasing median survival time (MST). In the control group MST was 9.0 days. Single i.p. injection of cisplatin increased MST by 116% (MST=19.5, p=0.008) compared with the control group. IPEC and HIPEC with cisplatin increased MST by 317% (MST=37.5, p<0.001) and by 183% (MST=25.5, p<0,003), correspondingly, compared with the control group. In comparison with IPEC without drug (MST=16.0) IPEC with cisplatin increased MST by 134% (p=0,002). Thus cisplatin administered with intraperitoneal chemoperfusions had the most significant cytostatic effects; however at IPEC regimen cisplatin had higher maximal tolerable dose and antitumor activity than at HIPEC regimen. IPEC with cisplatin may be more effective and less toxic than HIPEC with the drug and further clinical trials of these treatment regimens are warranted in ovarian cancer patients.

Biography :

V. G. Bespalov, is as Doctor of Medical Sciences, Head of Laboratory of Cancer Chemoprevention and Oncopharmacology, has been working in the N.N. Petrov Research Institute of Oncology during 30 years. He is member of an administrative Academic Council and a dissertational Academic Council of the N.N. Petrov Research Institute of Oncology, member of the Russian Oncological Society and the Russian Oncourological Society, scientific editor of Russian medical journals. He has published more than 130 papers in reputed journals and 20 monographies and books on the topics of cancer prevention, cancer chemoprevention, cancer chemotherapy, treatment of precancerous diseases, dietology and rehabilitation.